logo

For the Inventor, By the Inventor

Higashimurayama, Japan

Mototsugu Kabeya

This inventor holds 14 USPTO granted patents and 2 EPO patents. Top assignees: Kowa Company Limited, The University of Edinburgh, University of Strathclyde. Active years: 2001-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mototsugu Kabeya. Retrieved from https://idiyas.com/inventor/mototsugu-kabeya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14

% Patents Active = 21.4


Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 18(Granted Patents)


Location History:

  • Higashimurayama, JP (2001 - 2009)
  • Tokyo, JP (2011 - 2012)

Company Filing History:

goldMedal14 out of 605 
 
Kowa Company Limited
 patents
silverMedal1 out of 175 
 
The University of Edinburgh
 patents
bronzeMedal1 out of 151 
 
University of Strathclyde
 patents
where one patent can have more than one assignee

Years Active: 2001-2012

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents
1. 8268789 - PAR-2 antagonists (2012-09-18),
2. 8133864 - PAR-2 agonist (2012-03-13),
3. 7910556 - PAR-2 agonist (2011-03-22),
4. 7541339 - Par-2-activating peptide derivative and pharmaceutical composition using the same (2009-06-02),
5. 7196101 - Bis(5-aryl-2-pyridyl) derivatives (2007-03-27),
6. 6890940 - Bis(2-aryl-5-pyridyl) derivatives (2005-05-10),
7. 6828316 - Diamide compound and medicine containing the same (2004-12-07),
8. 6787653 - Preparation process of biphenylcarboxylic acid amide derivatives (2004-09-07),
9. 6706703 - Bis(5-aryl-2-pyridyl) derivatives (2004-03-16),
10. 6645957 - Cyclic amide compound (2003-11-11),
11. 6576642 - Diamide compounds and compositions containing the same (2003-06-10),
12. 6448242 - Cyclic amide compounds (2002-09-10),
13. 6340682 - Diamide compound and drugs containing the same (2002-01-22),
14. 6297283 - Diamide compounds and compositions containing the same (2001-10-02),

Title: **Mototsugu Kabeya: Innovator in PAR-2 Therapeutics**

Introduction

Mototsugu Kabeya is a notable inventor hailing from Higashimurayama, Japan. With an impressive portfolio of 14 patents, his work focuses primarily on advancing therapies related to the protease-activated receptor 2 (PAR-2). His inventions are significant contributions to the pharmaceutical field, particularly in creating compounds that exhibit potential therapeutic benefits against various diseases.

Latest Patents

Among his latest patents, Kabeya has developed PAR-2 antagonists, characterized by the general formula (1), which includes innovative compounds and their salicylic or solvated forms. These antagonists serve as preventive or therapeutic agents for PAR-2 related diseases. Additionally, he has produced a pharmaceutical composition aimed at preventing or treating conditions associated with PAR-2. The patented drug compositions have demonstrated improved PAR-2 activation potency when compared to existing peptide therapies, highlighting his contributions to enhancing pharmaceutical efficacy.

Career Highlights

Throughout his career, Kabeya has made substantial strides in drug development, making significant contributions while working with Kowa Company Limited and the University of Edinburgh. His dedication to research and development is evident through his numerous patents, showcasing his innovative spirit and commitment to medical advancements.

Collaborations

Kabeya has collaborated with notable professionals, including Hiroyuki Ishiwata and Seiichi Sato. These partnerships have likely propelled his research forward, enriching the field of pharmacology with their combined expertise and insights into therapeutic development.

Conclusion

Mototsugu Kabeya is a distinguished inventor whose work has greatly impacted the landscape of pharmaceutical innovations related to PAR-2. His patents mark a significant evolution in the development of therapeutic agents, making him a key figure in modern medical research. As the medical field continues to advance, Kabeya's contributions promise to play a vital role in future therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…